Paolo Bonome
Overview
Explore the profile of Paolo Bonome including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macchia G, Campitelli M, Pezzulla D, Lucci S, Fodor A, Russo D, et al.
Int J Radiat Oncol Biol Phys
. 2024 Sep;
121(3):693-702.
PMID: 39326506
Purpose: MITO-RT3/RAD (NCT04593381) is a prospective multicenter phase 2 trial designed to assess the effectiveness and safety of stereotactic body radiation therapy (SBRT) in patients who received diagnoses of oligometastatic...
2.
Boccardi M, Cilla S, Fanelli M, Romano C, Bonome P, Ferro M, et al.
Breast Cancer (Dove Med Press)
. 2024 Sep;
16:611-619.
PMID: 39310783
Purpose: The most prevalent treatment-related side effect related to adjuvant radiotherapy (RT) for breast cancer is acute skin toxicity in the irradiated area. The purpose of this single-institution pilot study...
3.
Cilla S, Macchia G, Bonome P, Pezzulla D, Romano C, Boccardi M, et al.
Med Dosim
. 2024 Sep;
50(1):57-62.
PMID: 39266381
Oligometastatic breast cancer patients can today could benefit from a multimodal approach, combining systemic therapy with metastasis-directed treatment using stereotactic body radiotherapy (SBRT). However, the possibility to synchronously treat multiple...
4.
Scrofani A, Valvano M, Lancellotta V, Pezzulla D, Vinci A, Cornacchione P, et al.
Br J Radiol
. 2024 May;
97(1160):1413-1422.
PMID: 38775716
Objectives: The prognosis of patients with perihilar-cholangiocarcinoma (PHC) is poor, with the majority presenting with unresectable disease at diagnosis. Palliative chemotherapy (CHT) is the standard treatment for unresectable PHC. Irreversible...
5.
Ferro M, Macchia G, Pezzulla D, Cilla S, Romano C, Ferro M, et al.
Br J Radiol
. 2024 May;
97(1159):1295-1301.
PMID: 38741392
Objectives: Stereotactic body radiotherapy (SBRT) and/or single fraction stereotactic body radiosurgery (SRS) are effective treatment options for the treatment of oligometastatic disease of lymph nodes. Despite the encouraging local control...
6.
Deodato F, Ferro M, Bonome P, Pezzulla D, Romano C, Buwenge M, et al.
Strahlenther Onkol
. 2024 Jan;
200(3):239-249.
PMID: 38180492
Purpose: DESTROY-4 (DOSE-ESCALATION STUDY OF STEREOTACTIC BODY RADIATION THERAPY) was a Phase I trial aimed to evaluate the safety and the feasibility of escalating doses of stereotactic body radiation therapy...
7.
Bonome P, Pezzulla D, Lancellotta V, Scrofani A, Macchia G, Rodolfino E, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136413
In patients with early-stage or recurrent NSCLC who are unable to tolerate surgery, a benefit could derive only from a systemic therapy or another few forms of local therapy. A...
8.
Pezzulla D, Re A, Cilla S, Ferro M, Romano C, Bonome P, et al.
Cancer Invest
. 2023 Oct;
41(9):774-780.
PMID: 37812173
Aims: This narrative review seeks to identify the SINS score application in the radiation oncology field. Methods: This literature review was performed searching papers on MEDLINE published from January 2010...
9.
Caivano D, Bonome P, Pezzulla D, Rotondi M, Sigillo R, De Sanctis V, et al.
Front Oncol
. 2023 Aug;
13:1163213.
PMID: 37601675
Introduction: Lymph node metastases (NMs) are a common site of tumor spread that can occur at different times of the disease. Stereotactic body radiation therapy (SBRT) can be a therapeutic...
10.
Macchia G, Pezzulla D, Campitelli M, Laliscia C, Fodor A, Bonome P, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(2):321-332.
PMID: 37150261
Purpose: This retrospective, multicenter study analyzes the efficacy and safety of stereotactic body radiation therapy in a large cohort of patients with oligometastatic/persistent/recurrent uterine cancer. Methods And Materials: Clinical and...